Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED -0.73%72 EV-to-EBITDA is 31.71 as of Aug. 22, 2026, which is 56% above its 10-year median of 20.36. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 72/100 and a GF Value™ of ₹453.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 739 Drug Manufacturers companies, Shilpa Medicare ranks worse than 80.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shilpa Medicare's enterprise value is ₹165,487 Mil.
Shilpa Medicare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹5,219 Mil. Therefore, Shilpa Medicare's EV-to-EBITDA for today is 31.71.
The historical rank and industry rank for Shilpa Medicare's EV-to-EBITDA or its related term are showing as below:
NSE:SHILPAMED'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.21 Med: 20.36 Max: 38.18
Current: 31.71
During the past 13 years, the highest EV-to-EBITDA of Shilpa Medicare was 38.18. The lowest was 9.21. And the median was 20.36.
NSE:SHILPAMED's EV-to-EBITDA is ranked worse than 80.92% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs NSE:SHILPAMED: 31.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shilpa Medicare's PE Ratio (TTM) for today is calculated as:
Shilpa Medicare's share price for today is ₹814.95.
Shilpa Medicare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14.155.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shilpa Medicare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's EV-to-EBITDA falls into.
Shilpa Medicare's current Enterprise Value is ₹165,487 Mil.
Shilpa Medicare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,219 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (NSE:SHILPAMED) has a EV-to-EBITDA of 31.71 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shilpa Medicare. This is 56% above median its historical median of 20.36. Over the past decade, Shilpa Medicare's EV-to-EBITDA has ranged from 9.21 to 38.18. According to the industry distribution chart, Shilpa Medicare ranks #598 out of 739 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Shilpa Medicare's EV-to-EBITDA too high?
Shilpa Medicare's current EV-to-EBITDA of 31.71 is 56% above median its 10-year median of 20.36. Over the past 10 years, this metric has ranged from a low of 9.21 to a high of 38.18. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Shilpa Medicare's value of 31.71 is 144.5% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #598 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #598 out of 739 companies for EV-to-EBITDA. This places Shilpa Medicare in the lower half of its industry. The industry median EV-to-EBITDA is 12.97. Shilpa Medicare's value of 31.71 is 144.5% above this benchmark. Historically, Shilpa Medicare's own EV-to-EBITDA has ranged from 9.21 to 38.18 over the past decade. While the company's 10-year median is 20.36 vs. the industry median of 12.97, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current EV-to-EBITDA of 31.71 is 144.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shilpa Medicare. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current EV-to-EBITDA is 31.71, which is 56% above median its own 10-year median of 20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹453.46, compared to a current price of ₹814.95 — trading 79.7% above its estimated fair value. The current EV-to-EBITDA is 31.71, which is 56% above median its 10-year median of 20.36 and 144.5% above the Drug Manufacturers industry median of 12.97. Shilpa Medicare's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current EV-to-EBITDA is 31.71 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹814.95 is trading 79.7% above its estimated GF Value™ of ₹453.46.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
EV-to-EBITDA: 31.71 (56% above median its 10-year median of 20.36)
GF Value™: ₹453.46 vs. price of ₹814.95 (79.7% above fair value)
Industry Position: 144.5% above the Drug Manufacturers median (#598 of 739)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
72GF Score
Get the complete analysis for NSE:SHILPAMED
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
